ETI41

ETI41 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 (IC50 = 0.63 μM) and TLR9 (IC50 = 0.16 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5) . ETI41 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI41 suppresses the expression of inflammation-associated genes and effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE) . ETI41 can be used for autoimmune and inflammatory diseases research[1].

Product Specifications

CAS Number

[2773474-99-8]

UNSPSC

12352005

Target

ERK; Interleukin Related; JNK; NF-κB; p38 MAPK; TNF Receptor; Toll-like Receptor (TLR)

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

CC(N1CCCN(C)C)=CC(C1=N2)=C(N)C3=C2CCCCCC3

Molecular Formula

C19H30N4

Molecular Weight

314.47

References & Citations

[1]Jeong U, et al. Discovery of ETI41 and ETI41: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases. Exp Mol Med. 2025 Sep;57 (9) :1951-1962.